X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (12) 12
cancer (9) 9
humans (9) 9
oncology (9) 9
article (7) 7
melanoma (7) 7
murine model (7) 7
animals (5) 5
proto-oncogene proteins b-raf - genetics (5) 5
vemurafenib (5) 5
braf (4) 4
immunology (4) 4
immunotherapy (4) 4
mutation (4) 4
care and treatment (3) 3
cell line, tumor (3) 3
colorectal cancer (3) 3
erk (3) 3
growth (3) 3
medicine, research & experimental (3) 3
research (3) 3
acute myeloid-leukemia (2) 2
antitumor activity (2) 2
base sequence (2) 2
biochemistry & molecular biology (2) 2
braf mutation (2) 2
braf mutations (2) 2
braf v600e mutation (2) 2
breast-cancer (2) 2
cancer biology (2) 2
cancer immunotherapy (2) 2
cell biology (2) 2
cells (2) 2
chronic lymphocytic-leukemia (2) 2
colorectal neoplasms - genetics (2) 2
colorectal neoplasms - pathology (2) 2
disease models, animal (2) 2
drug therapy (2) 2
extracellular signal-regulated map kinases - physiology (2) 2
gene expression regulation, neoplastic (2) 2
genetic aspects (2) 2
genetic engineering (2) 2
genetically modified organisms (2) 2
health aspects (2) 2
identification (2) 2
in-vivo (2) 2
kinase (2) 2
ligands (2) 2
lymphocytes (2) 2
lymphocytes t (2) 2
map kinase signaling system - drug effects (2) 2
map kinase signaling system - physiology (2) 2
medicine & public health (2) 2
metastases (2) 2
metastasis (2) 2
mice (2) 2
mitogen-activated protein kinase kinases - antagonists & inhibitors (2) 2
murine models (2) 2
neoplasms - metabolism (2) 2
pathology (2) 2
pathway (2) 2
perk (2) 2
phosphorylation (2) 2
physiological aspects (2) 2
protein kinases (2) 2
proto-oncogene proteins b-raf - antagonists & inhibitors (2) 2
ras (2) 2
research paper (2) 2
resistance (2) 2
t-cells (2) 2
targeted therapy (2) 2
thyroid diseases (2) 2
thyroid neoplasms - genetics (2) 2
tumors (2) 2
usage (2) 2
2-chlorodeoxyadenosine 2-cda (1) 1
3-phosphoinositide dependent protein kinase-1 (1) 1
a-c, anti-c-terminal (1) 1
a-n, anti-n-terminal (1) 1
ab, antibody (1) 1
abridged index medicus (1) 1
abrogate cytokine dependency (1) 1
aco, acyl coa oxidase (1) 1
acquired-resistance (1) 1
activatable cell penetrating peptide (1) 1
activated protein-kinase (1) 1
activated-receptor-gamma (1) 1
acute lymphoblastic-leukemia (1) 1
acute lymphocytic leukemia (1) 1
adenomas (1) 1
adult (1) 1
af, activating function (1) 1
agc (1) 1
aged (1) 1
aged, 80 and over (1) 1
akap12 (1) 1
alleles (1) 1
amino acid motifs (1) 1
amino acid sequence (1) 1
amino acid substitution (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Pigment Cell & Melanoma Research, ISSN 1755-1471, 05/2014, Volume 27, Issue 3, pp. 495 - 501
The BRAF V600E mutation, which approaches 50% in human melanomas, constitutively activates pERK and contributes to disease progression. The BRAF V600E... 
Cells | Melanoma | Vemurafenib | PLX4032 | cell culture | melanoma | Murine BRafV600E | pERK | B6 syngeneic mouse model
Journal Article
Matrix Biology, ISSN 0945-053X, 10/2015, Volume 48, pp. 66 - 77
Vertical growth phase (VGP) melanoma is frequently metastatic, a process mediated by changes in gene expression, which are directed by signal transduction... 
Human melanoma | Vemurafenib | MMP-1 | Murine melanoma | TGFβ | IL-8 | pERK | PERK
Journal Article
Journal of immunotherapy (Hagerstown, Md. : 1997), ISSN 1524-9557, 7/2012, Volume 35, Issue 6, pp. 473 - 477
Vemurafenib is an orally available small molecule that targets constitutively activated BRAFV600E, an integral part of the MAPK pathway involved in... 
vemurafenib | melanoma | BRAF | murine model | immunotherapy
Journal Article
Journal Article
British Journal of Cancer, ISSN 0007-0920, 02/2011, Volume 104, Issue 3, pp. 464 - 468
Journal Article
OncoImmunology, ISSN 2162-4011, 09/2014, Volume 3, Issue 10, pp. e959321-1 - e959321-12
IL-15 supports improved antitumor immunity. How to best incorporate IL-15 into vaccine formulations for superior cancer immunotherapy remains a challenge.... 
cancer vaccines | IL-15 | DC | INDUCTION | IMMUNOLOGY | CD8(+) T-CELLS | DNA VACCINE | ONCOLOGY | MEMORY PHENOTYPE | IN-VIVO | TRANS-PRESENTATION | ANTITUMOR IMMUNITY | MURINE MODELS | ESTABLISHED TUMORS
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 41, pp. 70281 - 70298
SSeCKS/Gravin/AKAP12 (SSeCKS) is a kinase scaffolding protein known to suppress metastasis by attenuating tumor-intrinsic PKC- and Src-mediated signaling... 
CXCL9/10 | Metastasis | Senescent secretome | CXCR3 | SSeCKS/AKAP12 | PROTEIN-KINASE | LYMPH-NODES | ONCOGENIC TRANSFORMATION | CELLULAR SENESCENCE | CELL BIOLOGY | senescent secretome | BREAST-CANCER | MURINE MODEL | metastasis | IN-VIVO | V-SRC | C-KINASE SUBSTRATE | CYTOSKELETAL ARCHITECTURE
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 11/2014, Volume 120, Issue 22, pp. 3446 - 3456
The mitogen‐activated protein kinase/extracellular signal‐regulated (MAPK/ERK) pathway is activated by upstream genomic events and/or activation of multiple... 
mitogen‐activated protein kinase (MAPK) | mitogen‐activated protein kinase‐kinase (MEK) | signaling | colorectal cancer | ovarian cancer | v‐raf murine sarcoma viral oncogene homolog (BRAF) | melanoma | extracellular signal‐regulated kinase (ERK) | Extracellular signal-regulated kinase (ERK) | Signaling | V-raf murine sarcoma viral oncogene homolog (BRAF) | Colorectal cancer | Melanoma | Mitogen-activated protein kinase (MAPK) | Mitogen-activated protein kinase-kinase (MEK) | Ovarian cancer | mitogen-activated protein kinase-kinase (MEK) | mitogen-activated protein kinase (MAPK) | v-raf murine sarcoma viral oncogene homolog (BRAF) | extracellular signal-regulated kinase (ERK) | RNA INTERFERENCE SCREEN | ACTIVATED PROTEIN-KINASE | BRAF(V600E) INHIBITION | ACQUIRED-RESISTANCE | POTENTIAL MECHANISM | TUMOR HETEROGENEITY | CELL LUNG-CANCER | MET AMPLIFICATION | ONCOLOGY | SIGNALING PATHWAY | BRAF MUTATIONS | Neoplasms - metabolism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | MAP Kinase Signaling System - physiology | Animals | MAP Kinase Signaling System - drug effects | Protein Kinase Inhibitors - therapeutic use | Humans | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Extracellular Signal-Regulated MAP Kinases - physiology | Calcium Signaling | Neoplasms - drug therapy | Care and treatment | Usage | Rapamycin | Protein kinases | Health aspects | Tumors | MEK | BRAF | MAPK | ERK
Journal Article
Leukemia, ISSN 0887-6924, 07/2011, Volume 25, Issue 7, pp. 1080 - 1094
The Ras/Raf/mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway is often implicated in sensitivity and resistance to... 
targeted therapy | Ras | therapeutic sensitivity | Raf | resistance | ERK | ABROGATE CYTOKINE DEPENDENCY | INITIATION-FACTOR 4E | ACUTE MYELOID-LEUKEMIA | KINASE INHIBITOR PROTEIN | DRUG-INDUCED APOPTOSIS | BONE-MARROW MICROENVIRONMENT | ONCOLOGY | ACUTE LYMPHOBLASTIC-LEUKEMIA | CHRONIC LYMPHOCYTIC-LEUKEMIA | MURINE HEMATOPOIETIC-CELLS | HEMATOLOGY | SIGNAL-REGULATED KINASE | ras Proteins - genetics | MAP Kinase Signaling System - physiology | Mitogen-Activated Protein Kinase Kinases - genetics | Apoptosis - drug effects | raf Kinases - antagonists & inhibitors | Humans | Neoplasm Proteins - physiology | Mitogen-Activated Protein Kinase Kinases - physiology | Extracellular Signal-Regulated MAP Kinases - antagonists & inhibitors | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Molecular Targeted Therapy | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Extracellular Signal-Regulated MAP Kinases - genetics | Gene Expression Regulation, Leukemic - genetics | raf Kinases - physiology | MAP Kinase Signaling System - genetics | Drug Design | Antineoplastic Agents - pharmacology | Extracellular Signal-Regulated MAP Kinases - physiology | Neoplasm Proteins - genetics | raf Kinases - genetics | ras Proteins - physiology | Cell Division - genetics | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | ras Proteins - antagonists & inhibitors | Gene Expression Regulation, Leukemic - drug effects | Leukemia - drug therapy | Cell Division - drug effects | Phosphatidylinositol 3-Kinases - genetics | Drug Resistance, Neoplasm - genetics | MAP Kinase Signaling System - drug effects | Models, Biological | Phosphatidylinositol 3-Kinases - physiology | Apoptosis - physiology | Drug Resistance, Neoplasm - physiology | Drug Resistance, Neoplasm - drug effects | Chemotherapy | Extracellular signal-regulated kinases | Leukemia | Physiological aspects | Genetic aspects | Research | Drug therapy | Health aspects | Mitogen-activated protein kinases | Cancer
Journal Article